R. Munuganti

发表

Identification of a potent antiandrogen that targets the BF3 site of the androgen receptor and inhibits enzalutamide-resistant prostate cancer.

A. Zoubeidi, R. Young, P. Rennie, 2014, Chemistry & biology.

Identification of novel androgen receptor inhibitors for the treatment of castration resistant prostate cancer

R. Munuganti, 2015 .

Discovery and characterization of a first-in-field transcription factor BRN2 inhibitor for the treatment of neuroendocrine prostate cancer

A. Zoubeidi, H. Beltran, C. Morrissey, 2022, bioRxiv.

Targeting the binding function 3 (BF3) site of the androgen receptor through virtual screening. 2. development of 2-((2-phenoxyethyl) thio)-1H-benzimidazole derivatives.

Artem Cherkasov, Eric Leblanc, Kate Frewin, 2013, Journal of medicinal chemistry.

Discovery of 1H-indole-2-carboxamides as novel inhibitors of the androgen receptor binding function 3 (BF3).

P. Rennie, F. Ban, A. Cherkasov, 2014, Journal of medicinal chemistry.

In silico discovery and validation of potent small-molecule inhibitors targeting the activation function 2 site of human oestrogen receptor α

P. Rennie, Kriti Singh, A. Cherkasov, 2015, Breast Cancer Research.

Abstract 1295: First-in-field small molecule inhibitors targeting BRN2 as a therapeutic strategy for small cell prostate cancer

A. Zoubeidi, H. Beltran, L. Puca, 2019, Experimental and Molecular Therapeutics.

Targeting Prostate Cancer Subtype 1 by Forkhead Box M1 Pathway Inhibition

A. Zoubeidi, K. Ketola, J. Bishop, 2017, Clinical Cancer Research.

The Nuclear Receptor Superfamily

P. Rennie, N. Lallous, Hélène Morin, 2016, Methods in Molecular Biology.

Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation

R. Young, P. Rennie, Kriti Singh, 2016, Molecular Cancer Therapeutics.

Characterization of a small molecule inhibitor of disulfide reductases that induces oxidative stress and lethality in lung cancer cells.

H. Varmus, G. Morin, S. Dixon, 2022, Cell reports.

A novel small molecule that induces cytotoxicity in lung cancer cells inhibits disulfide reductases GSR and TXNRD1

H. Varmus, G. Morin, S. Dixon, 2021, bioRxiv.

Targeting Semaphorin 3C in Prostate Cancer With Small Molecules

M. Gleave, J. Peacock, A. Cherkasov, 2018, Journal of the Endocrine Society.

Benzothiophenone Derivatives Targeting Mutant Forms of Estrogen Receptor-α in Hormone-Resistant Breast Cancers

P. Rennie, Kriti Singh, A. Cherkasov, 2018, International journal of molecular sciences.

Drug-Discovery Pipeline for Novel Inhibitors of the Androgen Receptor.

P. Rennie, A. Cherkasov, Kush Dalal, 2016, Methods in molecular biology.

Development of a Benzothiazole Scaffold-Based Androgen Receptor N-Terminal Inhibitor for Treating Androgen-Responsive Prostate Cancer.

A. Zoubeidi, Yu Chen, S. Bräse, 2021, ACS chemical biology.

Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy

C. Blattner, V. Orian-Rousseau, N. Jung, 2023, Cancer research communications.

In silico discovery and validation of potent small-molecule inhibitors targeting the activation function 2 site of human oestrogen receptor α

P. Rennie, Kriti Singh, A. Cherkasov, 2015, Breast Cancer Research.